Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease caused by excessive fat accumulation in the liver that induces chronic inflammation. Greater understanding of its pathogenesis and progression has led to the development of THR-β agonists and GLP-1/glucagon receptor agonists targeting obesity and other metabolic syndrome components. This session will review current diagnostic approaches, challenges associated with misdiagnosis and delayed diagnosis of MASH, and relevant guidelines to inform evidence-based care. The economic burden of MASH will also be addressed, highlighting opportunities for specialty and managed care pharmacists to optimize health care resource utilization and prepare them to support treatment access and coverage decisions for recently approved and emerging therapies.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: April 10, 2025
Expiration date: April 10, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the epidemiology, pathophysiology, clinical presentation and comorbidities, diagnosis, and burden of disease in metabolic dysfunction-associated steatohepatitis (MASH).
• Analyze the efficacy and safety profiles of approved and emerging therapies for treating MASH.
• Employ effective managed care strategies for optimizing patient outcomes using managed care insights to enable timely MASH diagnosis and enhanced access to evidence-based treatments.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-092-H01-P. The activity is available for CE credit through April 10, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Parvez S. Mantry, MD, AGAF, FAASLD, CPE, has the following relevant financial relationships with commercial interests to disclose: Grant/Research Support: Genentech, Genfit, Gilead, Intercept, Madrigal, Merck, Taiho; Consultant: Amgen, Novo Nordisk, Salix; Speakers Bureau: Amgen, Eisai, Gilead, Ibsen, Intercept, Madrigal, Novo Nordisk.

Nisha Bhide, PharmD, has the following relevant financial relationship with a commercial interest to disclose: Employee of PBM, Capital Rx: Director, Formulary.

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms